Gilead Sciences celebrates the groundbreaking of its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the co...
Research and Development Infrastructure Investment Expected to Create Hundreds of U.S. Jobs Amgen announced plans to invest more than ...
Regenerex Pharma, Inc. (OTC: RGPX), a leading innovator in advanced wound closure systems for chronic wounds, today announced that it has entered into a ...
Highly Complementary Technologies Strengthen Thermo Fisher’s Portfolio in Bioprocessing and Adjacent Markets Thermo Fisher Scientific Inc. , the w...
Secures third contract this year, reinforcing global competitiveness and expanding strategic partnerships LOTTE BIOLOGICS (CEO James Park) announce...
Foresight Diagnostics ("Foresight") announced that it has entered into a limited licensing agreement with Roche Molecular Systems and Roche Sequencing Sy...
SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to...
Bridge financing of $2.1 million supports initiation of pivotal Phase II study in 140 patients with microsatellite stable metastatic colorectal cancer, a...
Financing led by Fidelity Management & Research Company with participation from RiverVest Venture Partners, Lightchain Capital, LYZZ Capital, Abingw...
Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic...
Safety review leading to dose escalation and achievement of first predetermined enrollment target in Phase 1/2 study of SRP-1003 for DM1 triggers $100 ...
Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company” or “Rapid Micro”), an innovative life sciences technology company prov...
announced a $20 million credit investment from Catalio Capital Management, a leading investment firm dedicated to backing innovative healthcare com...
SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company focused on medicines for rare diseases and medical emergencies, and ...
© 2025 Biopharma Boardroom. All Rights Reserved.
